Arcellx, Inc. (ACLX)
Automate Your Wheel Strategy on ACLX
With Tiblio's Option Bot, you can configure your own wheel strategy including ACLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACLX
- Rev/Share 0.6344
- Book/Share 7.7893
- PB 14.6033
- Debt/Equity 0.1175
- CurrentRatio 3.9874
- ROIC -0.4451
- MktCap 6577351576.0
- FreeCF/Share -3.5551
- PFCF -32.6947
- PE -29.5397
- Debt/Assets 0.079
- DivYield 0
- ROE -0.5113
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ACLX | Rothschild & Co Redburn | Buy | Neutral | -- | $82 | Feb. 12, 2026 |
| Resumed | ACLX | UBS | -- | Buy | -- | $100 | Jan. 7, 2026 |
| Initiation | ACLX | Wells Fargo | -- | Overweight | -- | $100 | Dec. 22, 2025 |
| Initiation | ACLX | Wolfe Research | -- | Peer Perform | -- | -- | Nov. 18, 2025 |
| Initiation | ACLX | Stifel | -- | Buy | -- | $129 | Oct. 16, 2025 |
| Initiation | ACLX | Citigroup | -- | Buy | -- | $110 | June 17, 2025 |
| Initiation | ACLX | Redburn Atlantic | -- | Buy | -- | $109 | Oct. 8, 2024 |
| Initiation | ACLX | Cantor Fitzgerald | -- | Overweight | -- | -- | Sept. 3, 2024 |
News
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Arcellx, Inc. (NASDAQ: ACLX)
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Arcellx, Inc. (NASDAQ: ACLX ) related to its sale to Gilead Sciences, Inc. Under the terms of the proposed transaction, Arcellx shareholders are expected to receive $115.00 per share in cash plus one contingent value right of $5.00 …
Read More
Here's Why Shares of Arcellx Are Up Almost 80% Today
Published: February 23, 2026 by: Investopedia
Sentiment: Positive
Shares of a biotech firm are jumping on a down day for stocks.
Read More
Why is Arcellx stock up 80% today? Gilead's $7.8B answer
Published: February 23, 2026 by: Invezz
Sentiment: Positive
Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock's move wasn't a mystery rally.
Read More
ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Arcellx, Inc. (NASDAQ: ACLX) to Gilead Sciences, Inc. for $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. Halper Sadeh encourages Arcellx shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or zhalper@ha.
Read More
Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion
Published: February 23, 2026 by: WSJ
Sentiment: Positive
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.
Read More
Gilead to acquire Arcellx for $7.8 billion
Published: February 23, 2026 by: Reuters
Sentiment: Positive
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
Read More
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incura.
Read More
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incura.
Read More
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
Perceptive Advisors sold 1,002,282 Arcellx shares in the fourth quarter; the estimated trade size was $79.96 million based on quarterly average pricing. Meanwhile, the quarter-end value of the Arcellx position decreased by $107.06 million, reflecting both share sales and price changes.
Read More
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
Here is how Arcellx, Inc. (ACLX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Read More
Why Is Arcellx Stock Surging Today?
Published: December 08, 2025 by: Benzinga
Sentiment: Positive
Arcellx Inc. (NASDAQ: ACLX) shared new data on Saturday from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma (RRMM).
Read More
Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Arcellx (ACLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Arcellx, Inc. (NASDAQ:ACLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Rami Elghandour - Chairman of the Board, CEO & President Christopher Heery - Chief Medical Officer Michelle Gilson - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Good afternoon, everyone. Welcome to the session of the Morgan Salary Global Healthcare Conference.
Read More
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Published: May 14, 2025 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan.
Read More
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Read More
Arcellx Impressive Safety Data Leaves Doubts
Published: March 17, 2025 by: Seeking Alpha
Sentiment: Positive
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story.
Read More
About Arcellx, Inc. (ACLX)
- IPO Date 2022-02-04
- Website https://arcellx.com
- Industry Biotechnology
- CEO Rami Elghandour
- Employees 163